Coherus Presents Preliminary Results from Phase I Dose
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective...
Source: globenewswire.com
📰 Advanced Solid News
Advanced Solid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Solid. Real-time updates on events, politics, business and more.
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 -- Coherus BioSciences, Inc. today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the...
Source: marketscreener.com
Coherus Announces Presentation at the 2024 American Society
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...
Source: globenewswire.com
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXI...
Source: businessinsider.com
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer , in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4...
Source: marketscreener.com
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
BOSTON, Sept. 27, 2023 -- Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for...
San Diego United States Laras Sullivan Pyxis Oncology Inc Company Annual Report On Form Society For Immunotherapy Of Cancer
Source: marketscreener.com
Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug
/PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company...
South Korea United States Li Tang Biostar Pharma University Of Southern California Washington University School Of Medicine
Source: prnewswire.com
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of... | June 3, 2023
United States Markus Renschler Exchange Commission American Society Of Clinical Oncology Cyteir Therapeutics Inc Cyteir Therapeutics
Source: marketscreener.com
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast... | May 9, 2023
United States Michaelm Morrissey Sairopabv Sairopa Pharmaceuticals Inc Exchange Commission District Court
Source: marketscreener.com
Innate Pharma SA: Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKETprogram and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase
Source: finanznachrichten.de